CTOs on the Move

Valeant Pharmaceuticals

www.valeant.com

 
Valeant Pharmaceuticals International, Inc. is a diverse and decentralized pharmaceutical company that is committed to focusing on our key stakeholders while delivering consistently high performance. Our values provide the overall direction for our company, and provide us with the tools necessary to rise to any challenge by leveraging our collective hard work and effort along with our unwavering competitive spirit. These values help us set goals based on our organization’s potential and what we hope it will become.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.valeant.com
  • 2150 St. Elzéar Blvd. West
    Laval, QC CAN H7L 4A8
  • Phone: 514.744.6792

Executives

Name Title Contact Details
Michael McDaid
 Vice President of Information Technology Profile

Similar Companies

Emmaus Medical Inc.

Emmaus Medical Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Intersciences Inc

Intersciences Inc is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vanta Bioscience

Vanta Bioscience is a West Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Division of Industry Dynamics Associates

Division of Industry Dynamics Associates is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.